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Breast, ovarian and endometrial cancers cause significant morbidity and mortality. 
Despite the presence of existing screening, diagnostic and treatment modalities, 
they continue to pose considerable unsolved challenges. Overdiagnosis is a growing 
problem in breast cancer screening and neither screening nor early diagnosis of ovarian 
or endometrial cancer is currently possible. Moreover, treatment of the diversity of 
these cancers presenting in the clinic is not sufficiently personalized at present. Recent 
technological advances, including reduced representation bisulfite sequencing, 
methylation arrays, digital PCR, next-generation sequencing and advanced statistical 
data analysis, enable the analysis of methylation patterns in cell-free tumor DNA in 
serum/plasma. Ongoing work is bringing these methods together for the analysis of 
samples from large clinical trials, which have been collected well in advance of cancer 
diagnosis. These efforts pave the way for the development of a noninvasive method 
that would enable us to overcome existing challenges to personalized medicine.
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Screening & diagnosis
In the EU and the USA, one in every three 
individuals face a cancer diagnosis in their 
lifetime. In women, approximately half of all 
cancers originate in the female reproductive 
organs (i.e., breast, ovary, endometrium and 
cervix) [1,2]. Breast cancer (BC) is the most 
common cancer in women, affecting as many 
as one in eight women. The high mortality 
rate is related to its tendency to spread: a 
third of axillary, node-negative BC patients 
develop local or distant metastases, even in 
the absence of tumor spread at the time of 
primary diagnosis [3,4].
Ovarian cancer (OC) has low prevalence 
but is the most common cause of death from 
gynecological malignancies. In the early 
stages, women are mostly asymptomatic or 
present with nonspecific symptoms, making 
diagnosis difficult. However, while patients 
with stage I disease have a 5‐year survival 
of >90%, diagnosis is most often made at 
stage IIIC when 5‐year survival is less than 
40% [5]. The majority of patients with 
advanced stage disease undergo recurrence 
despite aggressive surgery and chemotherapy 
with platinum and taxanes [6]. Endometrial 
cancer (EC) is the most common gynecologi-
cal malignancy and, despite an overall 5‐year 
survival rate of 83%, it ranks second in mor-
tality among genital tract cancers, with the 
death rate steadily increasing over the past 
20 years [7]. EC is commonly diagnosed early, 
and is therefore often curable. However, the 
survival in advanced stages falls dramati-
cally to below 30% for stage III and 5% for 
stage IV. Additionally, the advanced disease, 
as well as serous papillary or clear cell can-
cer of the endometrium behave similarly to 
OC, meaning they are highly responsive to 
therapy prior to drug-resistant relapse [8,9].
Cervical cancer incidence and associated 
deaths have been reduced by up to 80% 
through introduction and widespread uptake 
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of triennial cervical screening with the Papanicolaou 
test (or Pap smear) [10]. Key factors in this success are 
the accessibility of the uterine cervix and availability 
of early stage markers – visualization of abnormal cells 
and/or HPV status.
By contrast, breast, endometrial and ovarian can-
cers continue to pose considerable challenges in terms 
of prediction and early detection. Unlike cervical can-
cer, the abnormal cells are not directly accessible. Fur-
thermore, in the case of OC, the cell of origin is not 
well defined.
Ovarian cancer
No effective screening method for OC is available 
at present. The US PLCO study comprised 78,216 
women aged 55–74 years, who were screened with 
CA125 and transvaginal sonography (TVS) annu-
ally or underwent usual clinical care. It did not find 
any difference in OC mortality between the screen-
ing and conventional care arms [11]. The UKCTOCS, 
the largest prospective randomized trial in the world, 
has enrolled over 200,000 postmenopausal women. 
It compared TVS alone with combined TVS and 
CA125 screening. The trial demonstrated 89.5% 
sensitivity, 99.8% specificity and a positive predic-
tive value (PPV) of 35.1% for the combination of 
methods (CA125 + TVS). For TVS alone, the values 
were 75.0% sensitivity, 98.2% specificity and 2.8% 
PPV [12]. Besides these promising results, the impact 
of screening on mortality remains to be determined, 
especially for individual subtypes of OC of different 
biological behavior and prognosis.
Beyond screening, once a pelvic mass is identi-
fied in a patient, a noninvasive test that could help 
to triage patient care would be highly desirable. Bio-
chemical markers, TVS, scoring systems and models 
are widely used to discriminate between benign and 
malignant disease. However, CA125 is also expressed 
in numerous benign conditions, and it is positive in 
only approximately 50% of early-stage OCs [13]. The 
Risk of Malignancy Algorithm, based on assessment 
of CA125 together with HE4, was initially thought to 
be superior to CA125 alone. However, other groups 
have suggested that further validation is required [14]. 
The Risk of Malignancy Index, a score based on ultra-
sound variables as well as on menopausal status and 
CA125, is widely used at present, mainly in the UK 
[15]. Although the Risk of Malignancy Index allows 
the referring gynecologist to send a patient to experts 
based on an objective assessment, its sensitivity is as 
low as 78% [16]. TVS by an expert operator using a 
formal scoring model system, is a highly sensitive 
and ideal second-stage diagnostic method; however, 
it is highly dependent on individual expertise [17]. As 
a result, discrimination between benign and malig-
nant ovarian tumor remains a significant challenge in 
clinical practice.
Availability of a biomarker or a panel of biomarkers 
that can detect OC in its earliest stages with both sen-
sitivity and specificity would improve outcomes. Bio-
markers may also be employed to identify some types 
of EC. In addition, they may be used as prognostic 
or predictive indicators, or as novel targets for cancer 
treatment.
Breast cancer
The lack of diagnostic markers detectable in early BC 
is a critical issue in patient management. In clinical 
practice, since early BC does not cause symptoms, 
mammography or ultrasound imaging are used for 
screening. Mammography screening, which detects 
characteristic masses and/or microcalcifications, is 
routinely performed in patients older than 45–50 years 
of age. Intensified breast screening can also be used for 
younger women when other factors, such as genetic 
profile or family history, indicate higher risk of disease.
Despite the fact that mammography screening 
for BC does save some lives, there is a continuing 
debate about its usefulness. Recent data demonstrate 
an improved treatment outcome for only 3–13% of 
women in whom BC was detected by screening mam-
mography. Consequently, it would seem that 87–97% 
of women with a screening-detected BC do not receive 
a clear treatment benefit, indicating that these can-
cers are still not being detected early enough [18]. In 
addition, there is convincing evidence that women 
diagnosed with BC not picked up during a screening 
program – so called ‘interval breast cancers’ – have 
significantly poorer prognosis [19]. Furthermore, over-
diagnosis is a growing concern. Cancers can be detected 
that would have otherwise naturally receded, or grow 
so slowly that the woman would die of other causes 
well before the cancer would produce any symptoms. 
The natural life course of BC was recently addressed in 
a cohort of 650,000 Swedish women, and it was found 
that BC incidence increased with biannual screening 
[20]. Based on these and data from previous studies [21], 
the estimated extent of overdiagnosis in BC screen-
ing programs is likely approximately 35%. However, 
the absolute risk reduction is only in the order of one 
in 1000 to one in 2000 women attending the screen-
ing programs [22]. A total of 92% of European women 
overestimated the true benefit of screening mammog-
raphy by at least one order of magnitude (tenfold), or 
they reported that they did not know [23]. In short, 
concerns about the potential risks and harms of the 
current breast screening program continue, as should 
the development of novel methods for early detection.
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Endometrial cancer
While EC is the most common malignancy of the 
female genital tract, routine screening is not recom-
mended [24], the rationale being that symptoms due to 
these malignancies develop at an early stage in 85% of 
cases [25]. Moreover, the screening methods have not 
yet been evaluated for their impact on cancer mortal-
ity. Endometroid EC has a good prognosis with 5‐year 
survival (depending on grade) of over 80% at early 
stage. However, up to 25% of ECs are of nonendo-
metroid type, meaning serous, clear-cell or mixed. 
Their prognosis is dramatically worse; similar to the 
prognosis of high-grade OC. These cancers typically 
spread in the pelvis very early and angioinvasion can 
be detected even in the absence of superficial inva-
sion of the myometrium [26]. Patients suffering from 
this type of EC would greatly benefit from improved 
screening.
Possible screening modalities for EC include mea-
suring endometrial thickness with TVS and endome-
trial sampling with cytological examination. If the 
same cut-offs were applied to the definition of abnor-
mal endometrial thickness in asymptomatic women 
[27] as used in symptomatic women [28], large numbers 
of false-positive results and unnecessary referrals for 
histological evaluations would follow. The Pap smear, 
successfully employed in the screening for cervical 
cancer, is not sensitive enough to reliably detect EC, 
although occasionally the Pap smear may identify 
endometrial abnormalities including EC.
Defining screening/diagnostic test 
characteristics
The development of a successful biomarker requires 
the precise definition of the clinical utility and the 
performance of the diagnostic test. Clinical utility 
defines the exact test populations, the follow-up pro-
cedures and decision diagrams. Depending on the 
clinical utility, specific thresholds for the test perfor-
mance need to be set, including sensitivity, specific-
ity and PPV (Figure 1). The experimental set-up for 
biomarker discovery, including sample composition, 
number of samples and type of critical control, as well 
as data analysis strategy, will critically depend on these 
predefined test requirements.
A major challenge when developing any diagnos-
tic test is to define the specific thresholds for test 
performance. If the follow-up diagnostic method is 
Figure 1. Effect of specificity and prevalence on assay outcomes. Shown are assay outcomes for a given sensitivity 
of 0.8 and two values of disease prevalence (0.1 and 0.01, respectively) plotted against assay specificity. Assay 
outcomes are TN’ (i.e., the number of TNs divided by the total number tested), FP’, TP’, FN’, PPV (i.e., the number 
of TPs divided by the total number of positive tests, which corresponds to the probability of having the disease if 
tested positive), and NPV (i.e., the number of TNs divided by the total number of negative tests). The graph shows 
clearly the strong dependency of PPV on prevalence, and its rapid decline with decreasing specificity. 
FN’: False-negative proportion; FP’: False-positive proportion; NPV: Negative predictive value; PPV: Positive 
predictive value; Prev: Prevalence; Sens: Sensitivity; TN’: True-negative proportion; TP’: True-positive proportion. 
For color images please see www.futuremedicine.com/doi/full/10.2217/epi.14.20
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noninvasive and highly specific, a screening test with 
high sensitivity is preferred. If the follow-up procedure 
is invasive, the test needs to be optimized for high 
specificity, even at the cost of lower sensitivity.
The goal of an early detection test for breast, ovarian 
or endometrial cancers would be to diagnose disease in 
women who are symptom-free. Early diagnosis of OC 
would significantly improve chances of curing the dis-
ease. For BC, the aim would be to improve on the cur-
rent screening method, either through improvement in 
diagnostic accuracy or via reduction of costs. A screen-
ing test of this type has to be easily administered, 
minimally invasive, convenient for the patient and 
affordable. In addition, it should not deliver incorrect 
results, in particular false-positive results.
The low prevalence of OC – between 0.4 and 0.6% 
of women aged above 50 years – poses a considerable 
challenge for screening test development. A PPV of 
10% and above could be regarded as acceptable in 
the case of OC screening. Given the low prevalence, a 
screening test would need to have a specificity of 97.8% 
or above, with a sensitivity of above 50% to achieve 
this PPV (Figures 2 & 3). A screening test should also 
detect high-risk ECs, which are comparable in terms 
of incidence and clinical behavior to OC.
Mammography screening can lead to early diag-
nosis of BC, resulting in less invasive surgery and the 
need for toxic systemic treatment in fewer patients. 
However, detection of benign or clinically irrelevant 
tumors causes harm to women through overtreatment. 
Regrettably, there is a high likelihood of side effects 
associated with the treatment, as well as psychologi-
cal, social and economic costs. Furthermore, after BC 
diagnosis, it remains unclear in a relevant number 
of cases, whether the individual patient will benefit 
from chemotherapy or other systemic or radiotherapy 
treatment approaches. The development of a method 
for early detection of primary or secondary BC with 
a high sensitivity and specificity would help to avoid 
overtreatment and psychological distress [29]. During 
systemic treatment, early information about treat-
ment efficacy would be invaluable and would help to 
prevent unnecessary side effects. The ideal test would 
be able to distinguish between benign and malignant 
lesions, most importantly being able to characterize 
the type of malignancy. It should be technically reli-
able and reproducible, while minimizing intra- and 
inter-observer variability. Thus, the testing system 
should be automated, or at least semi-automated. 
Finally, invasiveness should be reduced to a simple 
blood sample, making screening practicable in a wide 
variety of settings.
With these qualifiers in mind, it will be possible 
to advance biomarker discovery and development. 
However, this process is not without its challenges, as 
discussed in more detail below.
Past obstacles to biomarker development in 
women’s cancers
Strikingly, despite major advances in biomedical sci-
ence and analytical technologies, no novel biomarker 
has been approved for screening, diagnosis or moni-
toring response to adjuvant treatment in the field of 
women’s cancer in the last two decades. The US FDA 
last approved a biomarker in 2009 when HE4 protein 
analysis was approved for monitoring recurrence of 
OC. However, serum biomarkers for many diseases 
are employed in other areas of medicine (e.g., cardiac 
troponin for myocardial infarction, creatinine as an 
indicator of renal function, and choriogonadotropin 
confirming early pregnancy).
In 2001, Pepe and co-workers proposed a model 
consisting of five phases of biomarker development, in 
many ways similar to the recognized phases of drug 
development [30]. Below, we use this model to explain 
why past attempts to develop biomarkers for cancer 
screening have failed.
In Phase 1, potentially useful biomarkers are identi-
fied through comparison of tumor with non-neoplastic 
tissue/samples. The approach of comparing normal 
and cancerous tissue has not been feasible for proteomic 
analyses, which have relied on testing of serum/plasma. 
RNA is considered to be both analytically and bio-
logically less stable. Moreover, tools for genome-wide, 
especially epigenome-wide analyses, have only become 
available recently. Nonetheless, progress in this field 
has been impeded by technical difficulties and the lack 
of appropriate analysis platforms.
In Phase 2, clinical assays are developed based on a 
specimen (e.g., serum) that can be obtained noninva-
sively to differentiate subjects with cancer from those 
without, and provide insight into the true-positive 
rate and false-positive rate. As stated above, some 
approaches, including proteomics, are instigated at 
this second phase via direct analysis of serum or plasma 
from cancer patients at the time of diagnosis. Although 
this was successful at first, the majority of markers 
identified were in fact reflective of an inflammatory 
response, which is both unspecific and common in 
patients with an active cancer. To date, none of these 
markers have proven successful in diagnosing disease 
prior to the onset of clinical symptoms. An illustrative 
example was provided recently in our own work [31]. 
A DNA methylation (DNAme) signature identified in 
serum cell-free DNA from patients diagnosed with OC 
and age-matched controls, demonstrated a receiver-
operating characteristic area under the curve of 0.8. 
It was subsequently validated in an independent set of 
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cases and controls. Analysis of the genes involved in the 
signature, however, found that they were significantly 
enriched for markers that indicated an altered granu-
locyte/lymphocyte ratio in peripheral blood. Hence, it 
is extremely unlikely that this signature would indicate 
disease with the necessary level of sensitivity/specificity 
in a clinical setting.
Furthermore, although numerous clinical trials in 
breast and OC treatment have been performed in the 
past two decades, very few of the clinical trials cur-
rently reporting outcome data have collected serial 
samples, prior to and after systemic treatment in 
order to validate biomarkers. Consequently, a major 
hurdle for the identification of early detection can-
Figure 2. Approximating clinical assay characteristics for prevalence <<1. PPV can be described as a function of specificity, Sens 
and Prev as shown in the figure. However, the PPV may be approximated for small Prev (Prev <<1) as a function of specificity and 
a constant (Sens*Prev). Hence, for a given (constant) Prev, the curves each correspond to a particular level of Sens. During assay 
development, such a graph can be used to define target specificity and Sens of the biomarker panel when a certain PPV value has to 
be reached (in order to confer clinical utility): For example, one could first define a range of Sens deemed realistic (e.g., 0.2–1.0; to 
also cover the most optimistic case). These values, multiplied with the Prev, result in the set of (Sens*Prev) curves, which delimit the 
specificity range one has to aim for. A horizontal line may be drawn between those curves at the desired PPV, and the intersection 
between the line and the curves is used to look up the specificity needed for different Sens. Importantly, the horizontal line becomes 
much shorter and moves to the right with increasing PPV (since it always has to connect the same set of [Sens*Prev] curves for a 
given Prev and specificity range; e.g., see B & C). This illustrates the strong dependency upon Prev (i.e., how the required specificity 
increases drastically with lower prevalence, even when a broad range of Sens is allowed). Three examples for this approach are given 
(A, B & C); the estimated and exact specificity values for these examples are shown in the table. (The Prev numbers given for ovarian 
and breast cancer are arbitrary and only for illustration; see text for discussion on cancer epidemiology.). 
†Estimated assuming prevalence <<1. 
PPV: Positive predictive value; Prev: Prevalence; Sens: Sensitivity.
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cer biomarkers has been the lack of appropriately col-
lected and readily available sample sets for discovery 
and validation.
In Phases 3–5, clinical assays are validated in ret-
rospective longitudinal repository studies, in prospec-
tive screening studies (where the screen is applied 
to individuals and concurrent definitive diagnostic 
procedures applied to those who screen positive) 
and, eventually, in cancer control studies to address 
whether screening reduces the burden of cancer on 
the population. Sample collections made over signifi-
cantly long timeframes from sufficiently large num-
bers to include cancers with low prevalence and with 
appropriate sample processing are extremely rare. For 
these reasons, progress at Phase 3 has been largely 
thwarted. Additionally, studies examining the two 
serum markers PSA and CA125 (currently employed 
in prostate and OC screening) demonstrate incon-
sistencies with regard to their relative clinical value 
[12,32–34].
In summary, the key obstacles for success-
ful cancer biomarker development have been the 
lack of appropriate sample collections and available 
technologies.
Moving forward: DNAme-based cancer 
biomarkers
Over the past decade, we have seen intensified efforts 
to validate the involvement of epigenetic changes in 
cancer detection and monitoring. The best character-
ized epigenetic modification occurring during carci-
nogenesis is de novo methylation of CpG islands, cor-
relating with transcriptional repression of the affected 
genes [35]. Recent studies identify 10–15 tumor sup-
pressor genes in epithelial tumors that are silenced by 
mutations. The silencing of several hundred genes by 
DNAme demonstrate the important contribution of 
these modifications to tumor development [36,37].
These discoveries in the field of epigenetics high-
lighting the important role of DNAme in carcinogene-
sis create new opportunities to identify biomarkers for 
early detection and personalized treatment of cancer 
(Figure 4). Numerous reports have shown that methy-
lation signatures can be detected in virtually any body 
fluid (serum/plasma, smears, nipple fluid aspirate and 
vaginal fluid, among others). Blood samples can be 
obtained through a minimally invasive procedure and 
provide an ideal substrate for DNAme analysis. Cir-
culating cell-free DNA (cfDNA) is present in healthy 
Figure 3. True-positive versus false-positive rates needed for different positive predictive values, given a 
disease prevalence of 0.05. The characteristics of any biomarker assay can be drawn into this plot with a 
receiver-operating characteristic curve, and then used to determine the PPV that can be reached with this assay, 
and the sensitivity and specificity to which the assay has to be set; only when the receiver-operating characteristic 
curve is partially located to the left of a particular PPV threshold can that PPV be achieved. 
PPV: Positive predictive value.
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subjects at average concentrations of 30 ng/ml. If we 
are to assume that the DNA content of a normal cell 
amounts to 6.6 pg, this translates to an average of 5000 
genome equivalents per ml of blood. In cancer patients, 
tumor DNA is released into the blood by dying cancer 
cells and the average concentration of cfDNA in the 
serum is higher, approximately 180 ng/ml [38].
Analysis of tumor-specific DNAme in serum has 
a number of advantages compared with competing 
strategies:
•	 Improved sensitivity: cfDNA is easily amplified by 
PCR, with potential improvements in sensitivity;
•	 Fewer false positives: after acquiring meth-
ylation at a specific gene, the methylation pat-
tern is generally conserved throughout disease 
progression;
•	 DNAme is a positively detectable signal: rather 
than a loss of signal, as in chromosomal deletions;
•	 Stable during sample collection and transportation: 
abnormal DNAme is chemically and biologically 
stable and is relatively unaffected by physiological 
state and sample collection conditions;
•	 Increased technical sensitivity and specificity: 
gene-specific assays using real-time PCR are eas-
ily adapted to commercial platforms present in 
diagnostic laboratories;
•	 Assay design advantages: selection of gene pro-
moter CpG island hypermethylation offers 
advantages over genetic alterations that may be 
interspersed throughout a given gene.
As a result of the technical difficulties of DNAme 
analysis, the scant numbers of DNAme markers 
identified to date apply to only a fraction of breast, 
ovarian and endometrial cancers. They are nonspecific, 
lack sensitivity, and are based upon labor-intensive, 
non-quantitative techniques. Two separate technologi-
cal challenges arise. The first is the detection of tumor-
specific DNAme patterns that are present at particularly 
low abundance. This requires a high signal-to-noise 
ratio and often uses methylation-specific PCR priming 
and, in some cases, methylation-specific probing. The 
second is determination of the consecutive sequence 
of methylation sites in individual DNA molecules at 
single base-pair resolution, which requires low sensitiv-
ity, methylation-independent priming and combined 
Figure 4. Differentially methylated DNA biomarkers for early cancer detection. (A) Cell-free circulating tumor 
DNA from a blood sample for detection of breast and ovarian cancers from which tissue cannot be obtained 
readily; and (B) tumor DNA from vaginal fluid for the detection of endometrial and cervical cancers.
Ovarian or breast tumor Endometrial or cervical tumor
Differentially methylated cell-free circulating DNA
Early endometrial or cervical cancer
detection from a cervical swab
Early breast or ovarian
cancer detection from
a blood sample
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Figure 5. High-throughput methods including the Illumina Methyl 450k array and reduced representation bisulfite 
sequencing are used for DNA methylation discovery (facing page). (A) For the Illumina Methyl 450K array, DNA 
is treated with bisulfite to convert all unmethylated cytosines into uracil. During subsequent whole-genome 
amplification, uracil is replaced by thymine. DNA is randomly sheared; fragmented DNA is loaded onto the chip 
and hybridizes to either methylated (M) or unmethylated (U) probes. Binding of methylated loci to methylated 
probes leads to single base extensions and fluorescently tagged nucleotides. Analogously unmethylated loci bind to 
unmethylated probes. Finally, the proportion of incorporated fluorescent nucleotides is quantified for each probe. 
(B) Reduced representation sequencing enriches DNA for CpG rich regions by cleavage using a restriction enzyme 
(e.g., MspI being most commonly used). After enzymatic digestion, the ends of DNA fragments are repaired 
(filled with nucleotides) and sequencing adapters are ligated. Subsequently, the adapter-ligated DNA is bisulfite-
converted and amplified by PCR. Subsequent size selection by agarose gel electrophoresis ensures that only 
fragments having the restriction site (‘CCGG’ for MspI) on both ends within a small nucleotide range are sequenced. 
The DNA is extracted from gel, quality is controlled and the libraries are sequenced. By comparison of the sequence 
reads to a genomic reference, methylation rate for each cytosine present in the libraries is determined. 
WGA: Whole-genome amplification.
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PCR product resolution for sequence analysis. Until 
now, the high signal-to-noise-ratio required to detect 
scarcely abundant alleles within high background lev-
els of nontarget molecules has proved a major problem 
in applying DNAme assays for the clinical detection 
of cancer. However, the advent of digital MethyLight 
[39], discussed in more detail below, coupled with rapid 
advances in next-generation sequencing (NGS)-based 
technologies, such as those applied for the development 
of the PraenaTest™ (LifeCodexx, Germany), have 
provided novel ways to overcome this issue.
Technologies for whole-genome DNAme 
biomarker discovery
Recent advances in DNAme assay technology have 
the potential to enhance DNAme marker discovery by 
simultaneous analysis of many thousands of genomic 
loci. Additionally, it allows for an ultra-sensitive detec-
tion of negligible amounts of methylated DNA in a 
quantitative manner. DNAme profiling approaches can 
be divided into two main strategies: bisulfite conversion-
based methods and affinity enrichment methods, both 
of which can be analyzed either by microarrays or NGS.
Affinity enrichment technologies
Methylated DNA immunoprecipitation (MeDIP) 
uses antibodies specifically binding to 5-methylcyto-
sine [40]. Methylated DNA is enriched compared with 
unmethylated DNA, and genomic location can be deter-
mined using peak-calling algorithms. Accumulation of 
sequence reads indicates a high rate of cytosine meth-
ylation. A similar approach, methylated DNA capture 
by affinity purification sequencing (MeCAP), enriches 
DNA using methylated cytosine-binding proteins 
[41–43]. MeCAP enables the fractionation of bound DNA 
according to its GC content, providing detailed analysis 
of GC-rich regions [41].
These affinity enrichment methods have been 
extremely valuable in understanding the principles 
of DNAme on a genome-scale in both model systems 
and tumors. However, while these methods are use-
ful in detecting qualitative differences in methylation, 
they have reduced resolution – they cannot measure and 
differentiate methylation status of single CpGs – and 
sensitivity – they cannot reliably differentiate between 
low methylation and absence of methylation in a given 
region – and are especially sensitive to experimental 
batch effects, making cross-study comparisons 
challenging [44,45].
Bisulfite conversion-based strategies
In order to discover differentially methylated regions 
(DMRs; methylation present in tumor, absent in con-
trol DNA) from heterogenic tissue samples, the focus 
has moved to bisulfite conversion-based methods. 
Here, two approaches dominate: the Illumina Infinium 
Human Methylation 450 BeadChip arrays (Illumina, 
Inc., CA, USA) and NGS (Figure 5).
Microarrays
The Illumina 450K array, which measures the meth-
ylation status of approximately 480,000 cytosines 
in the human genome, enables DNAme profiling in 
population-wide studies. It offers moderate running 
costs and rapid data processing and analysis time. Of 
particular relevance to cancer biomarker studies, the 
450K array has been the method of choice for DNAme 
analysis by The Cancer Genome Atlas consortium [46]. 
This offers added value due to the availability of reference 
data for control tissues and pan-cancer analysis.
Next-generation sequencing
The current gold standard for DNAme analysis is the 
bisulfite conversion of DNA with subsequent sequenc-
ing [47,48]. NGS, with decreasing cost and increas-
ing throughput, may seem an obvious choice for an 
un biased genome-wide discovery approach. NGS pro-
vides single nucleotide resolution and larger numbers of 
CpG sites can be analyzed compared with the microar-
ray approach. Furthermore, repeat regions containing 
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about half of all CpGs within the human genome can be 
analyzed in greater detail [49]. However, whole-genome 
bisulfite sequencing (WGBS) using NGS is more costly 
and although it provides the means for cross-study com-
parisons, fewer reference data sets are available in the 
public domain.
A newly developed method, reduced representa-
tion bisulfite sequencing (RRBS) [50], utilizes the same 
approach as WGBS, but its libraries are enriched for 
CpG-containing motifs (Figure 5). RRBS enhances 
sequencing coverage of CpG dinucleotides and, by 
removing CpG-poor, constitutively methylated, 
C G
C
C
C
A
A
G
C G
C C
C C
C
C C
C
C
C
C
C C C
C C
G G
G G
G G G
G GG
G
G G
G
G G
G GG
C G
U G
T G
T
T T T
TTA
A
G
GT
T
T
G
G
Me
Me
Me Me
Me Me
Me
Me
Me
Me
M
M
U
U
C
C
C
G
G
C G
C A
CG
CG
A
T
A
TG
TG
Adapter
Adapter
Adapter
Adapter
Adapter
Adapter
Adapter
Adapter
MspI MspI
TISSUE Illumina Methyl 450k
Methylated
locus
Unmethylated
locus
Bisulfite
conversion
WGA and
fragmentation
Hybridization
Allele-specific
primer annealing
Single-base
extension
SERUM Reduced representation bisulfite sequencing
Genomic DNA
MspI digest, end repair,
A-tailing and adapter ligation
Bisulfite conversion and PCR
Size selection
D
N
A
 la
dd
er
Quality control
Final sequencing
libraries
Sequencing
320 Epigenomics (2014) 6(3) future science group
Review    Wittenberger, Sleigh, Reisel et al.
intergenic regions, provides data at single base-pair 
resolution for CpG islands, promoters and enhancer 
elements. The protocol includes digestion of DNA 
with restriction endonuclease MspI leading to high 
sequencing coverage for the areas subsequently repre-
sented – the reduced representation genome. This is a 
particular advantage for comparative DNAme profil-
ing as most fragments from this reduced representation 
genome will be sequenced in all RRBS analyses of a 
given species [51].
Another important difference of the discussed dis-
covery tools for DNAme is the amount of DNA avail-
able. Whereas microarrays and the enrichment meth-
ods such as MeDIP and MeCAP need DNA in the 
microgram range, RRBS as well as WGBS require far 
smaller amounts of DNA (∼50–100 ng) [52], which is 
a key consideration for a blood-based screening test. 
Moreover, circulating DNA in serum contains only 
small amounts of tumor DNA, whereas the majority 
of DNA derives from other cells [53]. Thus, the method 
for discovery of DMRs in serum/plasma DNA needs 
to be highly sensitive in order to discriminate between 
minimal differences in methylation levels. MeDIP and 
MeCAP detect regions of high methylation efficiently, 
but repetitive genomic elements can be detected as 
highly methylated in error and these methods are not 
as quantitative as RRBS [44,49].
Similar to the variety of different library prepara-
tion methods, many different NGS technologies exist 
and can be used for analysis of DNAme. The commer-
cial sequencing platforms available differ greatly with 
regard to read length, sequence reads per run, accu-
racy and costs [54,55]. The most-widely used sequenc-
ers are from Illumina and have been used in 5278 
publications (correct from 20 January 2014 [56]). The 
HiSeq 2000/2500 has by far the highest output of 
all sequencers (∼300 Gb), generating enough data to 
cover on average each base within the whole human 
genome about 100-times with a single flow cell. Fur-
thermore, it has the lowest costs per base and has been 
used for whole-genome bisulfite sequencing, as well 
as all other sequencing methods described above. 454 
sequencing has an output of approximately 700 Mb 
using Roche’s GS FLX+, but costs per base are cur-
rently above those of the Illumina system. Neverthe-
less, the mode read length of up to 700 bp has made 
it the gold standard for amplicon sequencing and it is 
used for targeted approaches analyzing DNAme. Life 
Technologies offers a NGS technology, which mea-
sures changes in electric charge instead of detection 
of fluorescent-labeled nucleotides, thereby avoiding 
the time-consuming image analysis step. Therefore, 
the run-time is significantly reduced compared with 
sequencers from Roche and Illumina. The sequenc-
ing output is currently about an order of magnitude 
higher than the GS FLX+ (10 Gb with Ion PI chip) 
output, but still about 30-times lower than the HiSeq 
2000/2500 output.
All three companies offer smaller-size, bench-
top versions of their sequencers. These have about 
ten-times less sequencing output and operate at higher 
costs per base. Nevertheless, they contribute to the 
spread of NGS technologies in universities and hospi-
tals. The PacBio RS II (Pacific Biosciences) does not 
require amplified DNA as input. Furthermore, it is 
able to assess DNAme (as well as other DNA modifi-
cations) without bisulfite treatment and has the longest 
read length (∼3.5 kb with P4-C3 chemistry). However, 
the sequencing output is only about 200 Mb and for 
the detection of CpG methylation an average cover-
age of 500× is needed. In addition, the PacBio RS II 
has high error rates per base (∼15–20%) and high costs 
per base. Therefore, it is not suitable for genome-wide 
analysis of human samples (although it can be used for 
high quality DNA modification analysis of bacteria).
Clinical DNAme assay platforms
In addition to whole-genome DNAme analysis for 
discovery of DMRs, there are targeted methods for 
DNAme analysis. Both targeted sequencing of DMRs 
and PCR-based methods are available, which enable 
DNAme biomarkers to be translated into clinical 
practice (Figure 6).
Methylation-specific PCR (MSP) is a relatively 
simple method that is more qualitative than quanti-
tative [57]. Two sets of primers for a target region are 
designed, one that amplifies the methylated template 
and one that amplifies the unmethylated template after 
bisulfite conversion. The PCR products of the two 
PCRs are then analyzed by agarose gel electrophore-
sis. To quantify the ratio of methylated and unmethyl-
ated DNA accurately, MethyLight combines MSP with 
real-time PCR [58]. An even more sensitive approach 
compared with real-time PCR involves digital PCR 
in combination with MSP in a method called digital 
MethyLight [59]. For digital PCR, the DNA template 
is extensively diluted out across multiple smaller PCR 
reactions. Each sub PCR reaction will subsequently 
contain none, one or more template molecules. Reac-
tions containing more than one template molecule are 
corrected for using Poisson statistics [60]. Currently 
available commercial digital PCR machines use emul-
sification of oil or microfluidics to generate hundreds 
to millions of reaction chambers. As digital PCR is 
usually not influenced by differences in PCR effi-
ciency and offers absolute quantification of the DNA 
template, it offers a superior sensitivity and specificity 
compared with real-time PCR [61].
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Figure 6. Clinical assay formats to analyze aberrantly methylated cell free DNA targets in cancer samples. 
(A) Analysis of bisulfite-modified cell-free DNA by digital PCR. Each individual sample is partitioned into 1000s of 
nanoliter partitions via oil emulsion and dispersion. Low abundant cancer-specific and differentially methylated 
targets are sequestered away from wild-type background DNA to increase the signal-to-noise ratio. The absolute 
number of target molecules is counted at end point PCR and expressed as number of molecules per volume of 
serum allowing patient samples to be compared. (B) Bisulfite sequencing of cell-free DNA derived from serum. 
Following bisulfite conversion, specific DNA regions that are aberrantly methylated in cancer samples can be 
analyzed at single base-pair resolution.
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Finally, ultra-deep sequencing of amplicons of bisul-
fite-converted DNA is used for gene-specific determina-
tion of DNAme [62]. The sensitivity and specificity of 
this approach can be increased by error correction tech-
niques such as SafeSeqS, which adds unique random 
barcodes to every DNA template [63]. Comparison of all 
sequence reads with the same barcode allows correction 
of errors introduced by PCR and sequencing and thus 
reduces the error rate remarkably.
Bioinformatics in DNAme biomarker 
discovery
The task of bioinformatics in the cancer biomarker 
discovery is to provide prioritized lists of marker can-
didates with the desired sensitivity and specificity. A 
DMR identification and ranking pipeline has to be 
established that includes threshold cut-offs for quan-
titative inclusion/exclusion criteria, and parameters for 
scoring and ranking of DMRs passing the thresholds 
(Figure 7). Criteria for identification and prioritization 
of marker candidates need to be carefully selected to 
take into account clinical relevance, as well as technical 
feasibility. Appropriate case–control discovery data sets 
have to be defined, covering not only the disease phe-
notypes in question, but all clinically relevant control 
specimens that could interfere with marker specificity 
(examples are given below).
A particular challenge for bioinformatics analysis in 
this field is that the clinical and discovery assays often 
rely on different technology platforms. The analysis 
needs to take into account technology-specific signal 
distribution, dynamic range and background signal. 
Discovery in samples from different tissues (e.g., solid 
tumor) to those used for diagnosis in the clinical rou-
tine (e.g., blood serum), increases the likelihood of fail-
ure in the validation phase. This problem can only be 
addressed by selecting a much higher number of discov-
ery marker candidates for validation and by prioritiz-
ing those markers that may be identified in serum (e.g., 
DNA markers from amplified genomic regions) [64].
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Figure 7. Pipeline overview for cancer differentially 
methylated region detection from Illumina 450K data. 
After the preprocessing and QC, DMR detection is 
carried out by comparing the methylation of cancer 
and WBC samples. After DMR detection, several steps 
and criteria are applied for filtering and ranking. 
DMR: Differentially methylated region; QC: Quality 
control; WBC: White blood cell.
Preprocessing and QC
DMR detection and ranking
Import raw data
Convert to β-values and M-values
Filter out unreliable probes and samples
based on detection p-values and/or
abnormal M-value profiles and signal
intensity distributions
Correct type 1 and type 2 probe ‘bias’
(intra-array normalization)
Correct for batch effect, if required
(inter-array normalization)
Statistical test to detect cancer-specific 
DMRs (vs most relevant control tissue; 
e.g., WBC): single probe or range approach. 
Exclude DMRs that show background 
hyper/hypo-methylation in WBC
Score and rank DMRs using the following criteria:
•  Cancer versus different control tissues effect
   sizes and p-values
•  No. of significant probes (confidence of DMR)
•  No. of CpGs present in DMR ± 60 bp (feasibility 
   to design clinical assay)
future science group
Review    Wittenberger, Sleigh, Reisel et al.
Achieving specificity
The bioinformatics workflow for biomarker discov-
ery must be informed by the clinical application 
anticipated. A particularly important aspect is the 
reduction of false-positive results. Accordingly, likely 
sources of contaminating (DNA) material have to be 
identified and the respective control tissues included, 
in order to score for marker specificity (Figure 8). If 
the goal is to deliver clinical assays based on cfDNA, 
the most likely source of contamination is cellular 
DNA in the circulation, namely white blood cells 
(WBCs). For this reason, WBCs should be considered 
the most stringent filter when searching for cancer-
specific methylation patterns in the serum. Large 
organs with high cell turnover, including the liver, 
lung and intestine, also release significant amounts 
of DNA into circulation. Therefore the availability 
and use of methylation data from these tissues in the 
bioinformatics analysis will improve the specificity of 
cancer DMRs and the accompanying clinical assay.
Clinical assay specificity with regard to cancer type 
and clinical stage also need to be considered care-
fully. In the case of BC, where overdiagnosis from 
mammography screening is a concern, biomarker 
discovery identifies cancers with poor prognosis and 
contrasts these against cancers with good prognosis 
as well as benign tumors. By contrast, the clinical 
assay for OC should detect all classes of the dis-
ease. During the discovery phase, histological clas-
sification is important to account for variability of 
the methylation pattern, thereby improving statisti-
cal power. To date, cancer biomarker discovery has 
focused on specific cancer types, often contrasting 
results against other cancer types. Recent literature 
has shown that different cancer types share several 
molecular features [65]. A search for shared methyla-
tion patterns rather than contrasting ones may be a 
more effective strategy.
Data analysis
Analyses of 450K array and bisulfite conversion NGS 
data present unique opportunities and challenges. As 
with any microarray, the 450K array relies on probe 
hybridization and is thereby sensitive to differences 
in probe affinity to methylated versus unmethylated 
DNA. An additional challenge for analysis of 450K 
array data is the presence of two different types of 
probe sets (type I and II) on the same array, and data 
from the two probe set types showing different dis-
tributions [66]. Robust normalization methods have 
been developed for correction of probe type differ-
ences [66–69]. However, it should be noted that use 
of different normalization methods here may lead to 
slightly incommensurate results and conclusions.
Another challenge, not generally acknowl-
edged, is individual probe-to-probe variation in 
affinity/sensitivity to unmethylated versus methyl-
ated DNA. This variation has little impact on priori-
tization of DMRs as long as no absolute thresholds 
for methylation levels (e.g., methylation in control 
sample should be below β-value 0.1) are applied 
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Figure 8. Example of potential differentially methylated region biomarker for early detection of ovarian cancer. Data from Illumina 
450K arrays is shown. (A) Normalized M-value profiles (arithmetic mean of the probes within the range) for all the relevant samples. 
(B) Normalized M-values of individual probes in the genomic context for ovarian cancer and WBC samples; 482 bp genomic region 
with four probes is shown. 
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and data analysis is done solely on the single probe 
level. However, if the goal of the analysis is to iden-
tify DMRs of several neighboring CpGs (see below), 
this background noise from probe-to-probe variation 
can have a significant effect. It may lead to false-
positives and -negatives when looking for homoge-
nously methylated or unmethylated genomic regions, 
respectively. Such an analysis therefore requires data 
that is corrected for a probe-specific background.
Compared with 450K array data, the NGS data 
has two main advantages: it does not suffer from 
probe-to-probe variation and it is fully quantita-
tive, thus providing superior sensitivity. However, 
the costs, the data volume and analysis throughput, 
prevent the application of NGS on large sample num-
bers. A specific challenge in the bioinformatic pro-
cessing of bisulfite sequencing data is data-mapping 
to the reference genome due to the reduced DNA 
sequence complexity. However, many bisulfite data-
specific mappers perform well [70,71]. After mapping, 
it is straightforward to calculate the percentage of 
methylation from the base calls. Another question 
that has not been addressed fully is the sensitive 
detection of few copies of methylated DNA within 
a high background of unmethylated DNA (and vice 
versa). Specific algorithms will need to be developed 
for effective detection of tumor-specific DMRs using 
heterogeneous tumor samples or samples containing 
a background of nontumor DNA, especially serum.
The search for DMRs as biomarker candidates has, 
in most of the cases, been performed at the single CpG 
level, especially for Illumina Infinium array data. For the 
older Infinium 27K array with low probe density, this 
was the only option. However, the newer 450K array 
has relatively high probe density in several genomic 
regions. Therefore, for both the 450K array and the 
NGS data, an analysis taking into account information 
of neighboring probes has a solid rationale and offers 
several benefits: DNAme status of neighboring CpGs 
in general is similar within genomic windows of a cer-
tain size and/or genomic features (e.g., transcription 
start site and enhancer, among others). Analysis of 
DNAme within such units with measurements of sev-
eral CpGs improves the power to detect DMRs [44], 
and reduces possible false-positive/negatives that may 
arise from technical or biological noise; several clinical 
assays suitable for blood-based tests require more than 
one CpG for sensitive measurement (e.g., PCR-based 
MethyLight, described above, requires 5–6 CpGs). By 
looking for these ‘co-methylated’ neighboring CpGs, 
the feasibility of the biomarker candidate DMR to per-
form in a clinical test is addressed early on. Identified 
DMRs are more likely to survive the rigorous clinical 
assay development process. However, algorithms mak-
ing use of the information on neighboring CpGs should 
do so based on the actual data rather than on annota-
tion of genomic features, as there still might be con-
siderable variation of methylation within such features.
324 Epigenomics (2014) 6(3) future science group
Review    Wittenberger, Sleigh, Reisel et al.
DMR detection at the single CpG level is straightfor-
ward; it is generally done with an appropriate two‐group 
statistical test, depending on the data transformation 
that has been applied, on cancer versus healthy tissue. 
The selection of the appropriate healthy control tissue is 
critical. If the goal is to develop a blood-based assay, we 
would recommend the use of WBCs. Effect-size calcu-
lated from the two-group test can be used for ranking 
the DMRs. For detection of genomic regions containing 
multiple differentially methylated CpGs, genome-wide 
bump-hunting [72], or a sliding-window approach can be 
used. Both methods identify DMRs with preferred win-
dow size and p (or q) value cut-offs, and an additional 
effect size can be calculated and used for ranking.
Once the DMRs from the primary tumor versus con-
trol tissue statistical test have been selected/ranked, fur-
ther available control tissue can be used for additional 
filtering and ranking. For both the single probe and 
multi-CpG range approaches, this can be carried out 
by applying two-group tests with p-value and effect size 
cut-offs. Once the information from all desired control 
tissues has been taken into account, further ranking can 
be done based on feasibility for the design of clinical 
assays. Principal criteria for feasibility are the number 
of CpGs within the DMR’s range or in the neighbor-
hood of the single CpG, depending on the strategy used. 
Further filtering can be performed based on biological 
annotation; for example, whether the range/CpGs is 
within a CpG island or CpG shore, and this informa-
tion may be used to establish hypothesis-derived test 
criteria.
Multiplexing
Even under optimal conditions, it is unlikely that a 
single marker would fulfil the high specificity require-
ments for population-wide, early detection of OC. A 
possible solution is to develop an assay with multiple 
read-out parameters, entailing multiple methylation 
sites or a combination of methylation and genomic 
markers. Here, the algorithm by which the measure-
ments are combined to yield a diagnostic result criti-
cally influences the sensitivity and specificity of the 
test. For example, the requirement for all parameters to 
reach a certain threshold (i.e., a Boolean AND combi-
nation) increases the specificity in a multiplicative way, 
while decreasing sensitivity. Similarly, allowing param-
eters to compensate for each other (OR combination) 
increases sensitivity at the cost of specificity.
Executive summary
Screening & diagnosis of breast, ovarian & endometrial cancers
•	 Breast cancer screening by mammography is offered routinely to women over 45–50 years of age, as well as to 
younger women considered to be at higher risk, but is complicated by overdiagnosis leading to unnecessary 
diagnostic procedures and treatment.
•	 The lack of an early screening or a diagnostic method for ovarian cancers often leads to diagnosis at a late 
stage of the disease, with associated poor survival for these women.
•	 Early detection of endometrial cancers that have poor prognostic features (e.g., clear cell and serous cancers) 
is likely to reduce mortality from these cancers.
Clinical sampling & sample collections
•	 A cancer screening marker has to be validated in a population-based setting and in samples predating 
diagnosis.
DNA methylation & epigenetic analysis
•	 Analysis of circulating tumor DNA and its epigenetic modification (methylation) in serum/plasma or vaginal 
fluid is a novel method for identification of cancer biomarkers.
•	 Reduced representation bisulfite sequencing offers a cost-effective alternative to whole-genome bisulfite 
sequencing for the identification of differentially methylated regions in DNA samples.
•	 In comparison to microarray-based methods, next-generation sequencing enables single nucleotide 
resolution, analysis of more CpG sites and analysis of samples containing as little as 30–50 ng DNA.
•	 Digital PCR is a targeted method that provides absolute quantification of a DNA template and can be used 
for sensitive and specific DNA methylation analysis with an increased signal-to-noise ratio compared with 
conventional methylation-specific PCR or MethyLight.
Bioinformatics
•	 Discovering cancer-specific methylated DNA regions requires novel bioinformatic tools to identify the most 
relevant and most promising regions that show a consistent methylation pattern across all linked CpGs of a 
particular region in the cancer sample and not in any normal sample (e.g., in white blood cells).
Future perspective
•	 Aberrant DNA methylation in serum/plasma or vaginal fluid will enable: early identification of individuals 
before the cancer becomes symptomatic and poses serious risk to well-being; and monitoring and 
personalization of cancer treatment.
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For the early detection of OC, a combined or 
sequential readout (Boolean AND) of DNAme mark-
ers with specific genomic features (cancer-specific 
mutations), and protein markers (CA125), would 
likely be required to reach 99.7% specificity. The 
measurement methods would ideally be independent 
(not correlated) and individually have a specificity of 
above 90%. It is also important that each individual 
method is able to detect the cancer at an early stage. 
Introducing a method that cannot detect OC in 
Stage 1/2 would make it fail in clinical practice. The 
combination of markers and test methods add signifi-
cant complexity to test development. All additions 
and combinations need to be planned for and tested 
carefully in the assay discovery and development 
process.
Conclusion & future perspective
The disappointingly slow progress in the field of bio-
marker development has been a major issue to date. 
Two of the major challenges are lack of appropri-
ate technologies and in depth knowledge of disease 
processes. Recent technological advances are now 
enabling us to finally progress in this field. Bio-
marker discovery has been aided by availability of 
microarrays and bisulfite sequencing and it is antici-
pated that those key biomarkers identified will both 
represent early disease and lead to improved under-
standing of tumorigenesis. Equally, technologies that 
are clinically suitable, such as digital MethyLight 
and ultra-deep sequencing of bisulfite converted 
DNA, will allow us to translate biomarker discov-
ery into clinically viable serum-based screening and 
diagnostic tests.
Newly identified serum DNAme biomarkers of 
female cancers will require validation in the clinical 
setting. Nevertheless, ongoing research in this field 
is likely to enable improved diagnosis and treatment 
monitoring for all major women’s cancers. Further-
more, the methods described will be suitable for 
wider application, and offer the vision of a single 
serum-based screening test for multiple cancers.
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